The forecast for biotech IPOs in 2017? Not nearly as hot as the industry would like
Last year only 28 biopharma companies managed to complete an IPO in the US, the worst record since the bad old days of 2012. And the smart money at Silicon Valley Bank says you can expect a repeat, or maybe something just slightly better, in the year ahead.
In other words, if you had to summarize SVB’s IPO projection for 2017, a shaky thumbs-up is about the best you’re going to get. The conga line of 2014 and 2015 has dissolved and shows no signs of reforming anytime soon.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
